Physician profile
Hema Dalal
NPI 1215963855
$1,477.68
in general payments reported to CMS, 2019-2025
18 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $28.72 · 2021: $120 · 2022: $209 · 2023: $165 · 2024: $441 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.46 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $489.63 | 2019-2025 | Dupixent |
| Kaleo, INC. | $161.00 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $149.17 | 2019-2021 | |
| Janssen Biotech, INC. | $126.75 | 2023-2024 | Tremfya, Stelara |
| Abbvie INC. | $109.37 | 2022-2025 | Rinvoq |
| Astrazeneca Pharmaceuticals LP | $84.31 | 2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $71.58 | 2024-2025 | |
| Redhill Biopharma INC. | $47.27 | 2020-2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.91 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $34.20 | 2021-2024 | Eohilia |
| Merck Sharp & Dohme LLC | $31.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.76 | 2025 | Tremfya |
| Ardelyx, INC. | $29.01 | 2023-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $17.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.67 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $14.14 | 2021 | |
| Alk-Abello, INC | $12.77 | 2019 | |
| Optinose US, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hema Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.